shenzhen salubris pharmaceuticals co., ltd.-凯发官网首页

news & trends

• 272022-07

  sal007 for the treatment of chronic heart failure approved by nmpa for clinical trial

• 282022-06

  updated progress of s086 tablets in phase 3 clinical trial for the treatment of chronic heart failure

• 282022-06

  updated progress of fotagliptin benzoate tablets in phase 3 clinical trial for the treatment of diabetes

• 212022-06

  salubris’ lamax laac® left atrial appendage closure system receives nmpa approval

• 272022-05

  updated progress of allisartan isoproxil and indapamide sustained-release tablets in phase 3 trial for the treatment of essential hypertension

• 242022-05

  salubris biotherapeutics announces new pipeline advancements and appointment of chief medical officer